50th week of 2014 patent applcation highlights part 36 |
Patent application number | Title | Published |
20140363420 | METHOD AND COMPOSITION FOR TOPICAL PAIN RELIEF - A method, product by process, and composition for aiding in pain relief. The user adds hot water to methylsulfonylmethane (MSM), then stirs the resulting mixture until the MSM is dissolved. The user then adds room temperature water, bromelain, aloe vera juice, and papain to the batch, and continues to stir. Coconut oil and palm kernel oil are stirred in, along with a sweet oil mixture. The sweet oil mixture is a mixture of natural, unconcentrated, oils such as lemon oil, sweet orange oil, arnica, sweet almond oil, peppermint oil, grape seed oil, comfrey oil, eucalyptus oil, grapefruit seed extract, and fragrance oils such as mango and kiwi. Finally, xanthan gum is stirred into the mixture, resulting in a batch of desired composition, which can be used topically for pain relief. | 2014-12-11 |
20140363421 | BIO-ACTIVE PEPTIDE SUPPLEMENT - A colostrum derived bioactive supplement derived of a number of cleaved protein fragments. The colostrum supplement is utilized with milk protein and Leucine to provide improved muscular function and exercise recovery. | 2014-12-11 |
20140363422 | METHOD OF PROVIDING MONOCLONAL AUTO-ANTIBODIES WITH DESIRED SPECIFICITY - Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human Auto-Immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy of are described. | 2014-12-11 |
20140363423 | PEPTIDE COMPOUNDS FOR INHIBITION OF PLATELET AGGREGATION - The invention relates to a peptide compound and its pharmaceutical composition for inhibiting platelet aggregation and preventing/treating thrombogenic diseases. The invention develops pentapeptides and hexapeptides derived from snake venom C-type lectin-like proteins (CLPs) fragments, which can inhibit platelet aggregation and have antithrombotic activity without hemorrhagic tendency. Accordingly, they can be used as potential agents for the prevention and therapy of thrombogenic diseases. | 2014-12-11 |
20140363424 | USE OF CHIMERIC ANTI-CD20 ANTIBODY AS IN VITRO OR IN VIVO PURGING AGENT IN PATIENTS RECEIVING BMT OR PBSC TRANSPLANT - The use of anti-CD | 2014-12-11 |
20140363425 | SYSTEMS AND METHODS FOR IDENTIFYING CANCERS HAVING ACTIVATED PROGESTERONE RECEPTORS - Systems and methods for identifying tumors having activated progesterone receptors are provided. Patients suspected of having a tumor susceptible to growth inhibition by anti-progestins can be treated with an anti-progestin. | 2014-12-11 |
20140363426 | HETERODIMERIC PROTEINS - In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, wherein the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain. | 2014-12-11 |
20140363427 | ANTI-HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTIBODIES AND METHODS OF USE - Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided. | 2014-12-11 |
20140363428 | THERAPEUTIC ANTIGEN-BINDING MOLECULE WITH A FcRn-BINDING DOMAIN THAT PROMOTES ANTIGEN CLEARANCE - The present invention provides: a modified FcRn-binding domain having an enhanced affinity for the Fc Receptor neonatal (FcRn) at neutral pH; an antigen-binding molecule comprising said FcRn-binding domain, which has low immunogenicity, high stability and form only a few aggregates; a modified antigen-binding molecule having an increased FcRn-binding activity at neutral or acidic pH without an increased binding activity at neutral pH for a pre-existing anti-drug antibody; use of the antigen-binding molecules for improving antigen-binding molecule-mediated antigen uptake into cells; use of the antigen-binding molecules for reducing the plasma concentration of a specific antigen; use of the modified FcRn-binding domain for increasing the total number of antigens to which a single antigen-binding molecule can bind before its degradation; use of the modified FcRn-binding domain for improving pharmacokinetics of an antigen-binding molecule; methods for decreasing the binding activity for a pre-existing anti-drug antibody; and methods for producing said antigen-binding molecules. | 2014-12-11 |
20140363429 | BINDING MOLECULES SPECIFIC FOR HER3 AND USES THEREOF - The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction. | 2014-12-11 |
20140363430 | Activatable Antibodies that Bind Interleukin-6 Receptor and Methods of Use Thereof - The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to interleukin-6 receptor (IL-6R), and to methods of making and using these anti-IL-6R activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications. | 2014-12-11 |
20140363431 | METHODS FOR TREATING PROGRESSIVE MULTIPLE SCLEROSIS - The present invention concerns methods for treating progressive multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use. | 2014-12-11 |
20140363432 | VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS AND USES THEREOF - The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided. | 2014-12-11 |
20140363433 | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same - In one aspect, the invention provides a method of making a bioactive peptide-bearing antibody, or fragment thereof, comprising (a) engrafting the amino acid sequence of at least one bioactive peptide of interest into (i) at least one of CDR-H1, CDR-H2 or CDR-H3 of a heavy chain variable region comprising one or more chicken framework regions and/or (ii) at least one of CDR-L1, CDR-L2 or CDR-L3 of the light chain variable region comprising one or more chicken framework regions, and (b) determining whether the antibody has substantially the same biological activity as the bioactive peptide. | 2014-12-11 |
20140363434 | BINDING AGENTS TO INTRACELLULAR TARGET MOLECULES - The application provides polypeptides comprising or essentially consisting of at least one Alphabody, wherein said Alphabody is capable of internalization into a cell and specifically binds to an intracellular target molecule. The application further provides nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions, and in particular to pharmaceutical compositions, that comprise such polypeptides, nucleic acids and/or host cells; and uses of such polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes. | 2014-12-11 |
20140363435 | KLOTHO BETA - The invention concerns uses of anti-KLβ agents, and detection of KLβ and/or FGF19 and/or FGFR4. | 2014-12-11 |
20140363436 | DIAGNOSING AND TREATING IGA NEPHROPATHY - Provided are methods of diagnosing IgA nephropathy in a subject. Optionally, the methods comprise isolating an IgG from the subject and determining whether the IgG binds to a galactose-deficient IgA1. Optionally, the methods comprise providing a biological sample from the subject and detecting in the sample a mutation in a IGH gene, wherein the mutation is in a nucleotide sequence encoding a complementarity determining region 3 (CDR3) of a IGH variable region. Optionally, the methods comprise determining a level of IgG specific for a galactose-deficient IgA1 in the subject. Also provided are methods of treating or reducing the risk of developing IgA nephropathy in a subject. | 2014-12-11 |
20140363437 | COMBINATION THERAPY FOR A STABLE AND LONG TERM ENGRAFTMENT - A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×10 | 2014-12-11 |
20140363438 | NEUREGULIN ANTIBODIES AND USES THEREOF - The invention provides anti-neuregulin1 antibodies and methods of using the antibodies in treating diseases or disorders, such as cancer. In a particular embodiment, the anti-neuregulin1 antibodies bind to both neuregulin1α and neuregulin 1β isoforms. | 2014-12-11 |
20140363439 | ANTI-LRP6 ANTIBODIES - The invention provides anti-LRP6 antibodies and methods of using the same. A particular aspect of the invention provides for bispecific anti-LRP6 antibodies that inhibit signaling by multiple Wnt isoforms. | 2014-12-11 |
20140363440 | ANTIBODIES AND THEIR USES FOR DIAGNOSIS AND TREATMENT OF CYTOMEGALOVIRUS INFECTION AND ASSOCIATED DISEASES - Anti CMV antibodies are provided. Thus an antibody of the present invention comprises an antigen recognition domain capable of binding an MHC molecule being complexed with a cytomegalovirus (CMV) pp65 or pp64 peptide, wherein the antibody does not bind said MHC molecule in an absence of said complexed peptide, and wherein the antibody does not bind said peptide in an absence of said MHC molecule. Also provided are methods of using the antibodies. | 2014-12-11 |
20140363441 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLUENZA - The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection. | 2014-12-11 |
20140363442 | THERAPEUTIC CD47 ANTIBODIES - Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to CD47 of multiple mammalian species, block the binding of SIRPalpha and TSP1 to CD47, promote phagocytosis of susceptible cancer cells, and reverse TSP1 inhibition of nitric oxide signaling, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47 and that exhibit similar biological activities. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents for treating susceptible cancer cells, promoting their phagocytic uptake and clearance. | 2014-12-11 |
20140363443 | TRICYCLIC CARBAMATE JAK INHIBITORS - The present disclosure relates to 2,4-pyrimidinediamines substituted with tricyclic carbamates and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, such as JAK2 or JAK3, is therapeutically useful. | 2014-12-11 |
20140363444 | Anti-IL-23 Antibodies - The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same. | 2014-12-11 |
20140363445 | METHOD OF TREATING CANCER COMPRISING A VEGF-B ANTAGONIST - The present invention relates generally to the field of cancer therapy and prophylaxis. More particularly, the present invention provides growth factor antagonists which inhibit the growth of cancers including tumors and pre-cancerous tissue. Even more particularly, the present invention is directed to antagonists of vascular endothelial growth factor-B and their use to inhibit the growth of cancer including tumor tissue and pre-cancerous tissue. | 2014-12-11 |
20140363446 | POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS - This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development. | 2014-12-11 |
20140363447 | Protofibril-Binding Antibodies And Their Use In Therapeutic And Diagnostic Methods For Parkinson's Disease, Dementia With Lewy Bodies And Other Alpha-Synucleinopathies - Antibodies and fragments thereof have high affinity for human α-synuclein protofibrils and low binding of α-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting α-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with α-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with α-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with α-synuclein pathology, and in methods for reducing or inhibiting α-synuclein aggregation by administration of such an antibody or fragment. | 2014-12-11 |
20140363448 | CDCP1 AND BREAST CANCER - The present invention relates to a method for treating breast cancer in a subject having a hyperactivation of the Epidermal Growth Factor Receptor 1 and/or 2 (EGFR and/or ErbB2 HER2), as compared to the normal subject population, or expressing deltaHER2, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the CUB domain-containing protein 1 (CDCP1). | 2014-12-11 |
20140363449 | METHODS, ASSAYS, AND SYSTEMS RELATING TO SAKT - The technology described herein is directed to methods, assays, and systems relating to determining the level of SAKT signaling activity in a sample obtained from a subject as well as methods relating to administering inhibitors and/or agonists of SAKT signaling. | 2014-12-11 |
20140363450 | Oxidized Cardiolipin as a Novel Pro-Inflammatory Factor - Low levels of antibodies reactive with oxidised Cardiolipin (oxCL) in mammals are related to an increased risk of developing cardiovascular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxCL. Thus, based on their relations methods of monitoring, determining and diagnosing as well as methods of immunisation and therapy of these diseases and conditions are provided. | 2014-12-11 |
20140363451 | Anti-FOLR1 Immunoconjugate Dosing Regimens - Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects. | 2014-12-11 |
20140363452 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF - The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer. | 2014-12-11 |
20140363453 | Methods for Increasing Efficacy of FOLR1 Cancer Therapy - Methods to improve the success of cancer therapies that target the human folate receptor 1 are provided. Kits comprising reagent useful in the methods are further provided. | 2014-12-11 |
20140363454 | Antibody-Drug Conjugates, Compositions and Methods of Use - Antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, tubulysin analogs, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers. | 2014-12-11 |
20140363455 | DLL3 MODULATORS AND METHODS OF USE - Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided. | 2014-12-11 |
20140363456 | TUMOR-SPECIFIC GM-CSF CYTOKINE RESPONSE AS PREDICTOR OF CANCER VACCINE EFFECTIVENESS - The present invention relates to methods of treating cancer with a cancer vaccine using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a biomarker; methods of prognosticating an outcome of cancer treatment with a cancer vaccine using GM-CSF as a biomarker; methods for qualifying subjects for cancer vaccination using GM-CSF as a biomarker; methods for comparing the efficacy of two or more cancer vaccine treatments based on GM-CSF response; and kits for the effective treatment of cancer. | 2014-12-11 |
20140363457 | 2-THIO-1,3,4-OXADIAZOLES AZETIDINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - The present invention relates to 2-thio-1,3,4-oxadiazoles azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2014-12-11 |
20140363458 | MALARIA VACCINE - The present invention provides a particle comprising a polypeptide and at least one malaria antigen, and a composition or vaccine comprising thereof, its use in medicine, particularly in the prevention or treatment of malaria infections. | 2014-12-11 |
20140363459 | SYNTHETIC CAPSID PROTEINS AND USES THEREOF - The present invention relates to synthetic proteins and the uses thereof. More particularly, the invention relates to synthetic Circovirus type capsid proteins with improved properties. These proteins, or the coding nucleic acids, are useful e.g., to generate antibodies, immunogen compositions, or vaccines. The invention further relates to methods for treating and/or preventing PCV2-associated diseases in mammals using said proteins, nucleic acids or compositions. The invention also relates to compositions and methods for detecting PCV2 in a sample, using the above proteins, nucleic acids, or antibodies. | 2014-12-11 |
20140363460 | COMBINED ANTIGEN AND DNA VACCINE FOR PREVENTING AND TREATING RSV INFECTION - The present disclosure relates to treating and preventing symptoms of respiratory syncytial virus (RSV) infection using a combination vaccine containing an RSV antigen and a DNA encoding the RSV antigen. | 2014-12-11 |
20140363461 | ADJUVANTED FORMULATIONS OF STAPHYLOCOCCUS AUREUS ANTIGENS - The efficacy of | 2014-12-11 |
20140363462 | HETEROLOGOUS EXPRESSION OF NEISSERIAL PROTEINS - Alternative and improved approaches to the heterologous expression of the proteins of | 2014-12-11 |
20140363463 | SHORTENED PURIFICATION PROCESS FOR THE PRODUCTION OF CAPSULAR STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDES - A shortened process for producing a solution containing substantially purified capsular polysaccharides from a cellular | 2014-12-11 |
20140363464 | PRE- OR POST-EXPOSURE TREATMENT FOR FILOVIRUS OR ARENAVIRUS INFECTION - The compositions and methods of the invention described herein provide pre- or post-exposure treatments against filovirus or arenavirus infection by expressing one or more genes (e.g., two or more genes) from filoviruses or arenaviruses in a delivery vehicle (e.g., a recombinant viral vector or a liposome). | 2014-12-11 |
20140363465 | MYCOBACTERIAL VACCINE VECTORS AND METHODS OF USING THE SAME - Mycobacterium bovis BCG is a potent stimulator of the cellular immune response and has potential as a recombinant vaccine vector. Disclosed are BCG strains that generate greater MHC class I presentation of a transgenic protein, relative to the unmutated parental strain, and that improve a recipient's CD8+ T cell response against the transgenic protein following vaccination. The mycobacterial constructs and their respective t/ansposon mutant BCG strains exhibit increased immunogenicity that is several times greater than responses generated by the parental strain and other existing modified rBCG strains. Furthermore, upon introducing the SIV gag gene into these novel strains, we observed that these strains primed for increased CD8+ T cell responses in a heterologous prime/boost regimen, comparable to levels generated by plasmid DNA vaccines. Creation of a second generation rBCG vector that may be utilized as a vaccine vector for immunizing against a variety of pathogens. | 2014-12-11 |
20140363466 | METHOD OF TREATING PREGNANT COWS AND/OR HEIFERS - The present invention relates to combination vaccines for the prophylaxis and treatment of microbiological infections in cattle which comprise an attenuated bovine viral diarrhea virus (BVDV) for the the prophylaxis and treatment of BVDV caused infections. The invention also relates to a method of vaccinating a pregnant cow. | 2014-12-11 |
20140363467 | AVIAN INDUCED PLURIPOTENT STEM CELLS AND THEIR USE - The present invention relates to the production of avian induced pluripotent stem cells from non-pluripotent somatic cells, including embryonic fibroblasts and adult somatic cells. In this method, avian (including quail or chicken) somatic cells are reprogrammed into a state closely resembling embryonic stem cells including the expression of key stem cell markers alkaline phosphatase, etc. by transfecting/transducing the non-stem cells with genes (preferably using a non-integrating vector as otherwise described herein or alternatively an integrating vector, such a lentiviral vector, retroviral vector or inducible lentiviral vector, among others) which express at least nanog, Lin28 and cMyc. In preferred aspects of the invention, the transfected/transduced vectors express nanog, Lin28, cMyc, Oct 4 (POU5F1 or PouV), SOX2 and KLF4. The induced stem cells which are produced contribute to all 3 germ layers, the trophectoderm and in certain aspects, the gonad in chimeric offspring. | 2014-12-11 |
20140363468 | COMBINED INFLUENZA VACCINES FOR SEASONAL AND PANDEMIC PROTECTION - Current approaches to influenza vaccination focus either on seasonal strains or pandemic strains. Current seasonal vaccines typically include antigens from two influenza A strains (H1N1 and H3N2) and one influenza B strain. Current pandemic vaccines focus on H5N1 influenza A virus strains. It is an object of the invention to provide further and improved ways of preparing vaccines that can raise immunity against both seasonal and pandemic strains. | 2014-12-11 |
20140363469 | VIRAL ATTENUATION AND VACCINE PRODUCTION - The present invention is directed to the generation of attenuated viruses or viral transcripts for the production of vaccines by incorporating microRNA binding sites within the viral target sequence of the pathogen. | 2014-12-11 |
20140363470 | PHARMACEUTICAL FORMULATIONS AND THE USE THEREOF FOR THE TREATMENT OF PEANUT ALLERGY - The present invention relates to compositions which can be used in immunotherapy and especially to compositions which can be used in immunotherapy for mammals, such as human mammals, suffering from peanut allergy. The present invention further relates to the use of the present compositions for the therapeutic treatment for desentizing the immune system of a mammal suffering from an allergy by immunotherapy and the use of the present compositions in a prophylactic treatment of a mammal with high predisposition to develop a certain allergy. Specifically, the present invention relates to pharmaceutical compositions comprising a modified whole peanut extract and pharmaceutically acceptable diluents and/or excipients, wherein said modified whole peanut extract is a reduced and subsequently alkylated whole peanut extract, preferably a whole defatted peanut extract comprising soluble peanut kernel proteins such as Ara h1, Ara h2 and Ara h6. | 2014-12-11 |
20140363471 | METHOD OF INDUCING AUTOPHAGY AND ACTIVATING TOLL-LIKE RECEPTOR - A method of inducing autophagy in a cell is achieved by contacting the cell with graphene oxide (GO) in an amount effective to induce autophagy in the cell, wherein the cell expresses at least one of TLR-4 (Toll-like receptor 4) and TLR-9 (Toll-like receptor 9). Differences between autophagy triggered by GO and other conventional agonists such as rapamycin have been observed. GO may activate autophagy in some cells that may not be triggered by rapamycin. The cell reveals no apparent apoptosis after treatment of the graphene oxide. A method of activating a Toll-like receptor in a cell is also herein provided. | 2014-12-11 |
20140363472 | METHODS FOR PREDICTING THE SURVIVAL TIME OF A PATIENT SUFFERING FROM A SOLID CANCER BASED ON DENSITY OF B CELLS - The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising the steps consisting of i) determining the density of B cells at the invasive margin of the tumor (im) in a tumor tissue sample obtained from said patient, ii) comparing said density with a predetermined reference value and iii) providing a good prognosis when the density of B cells at the invasive margin of the tumor is higher than the predetermined reference value and a poor prognosis when the density of B cells at the invasive margin of the tumor is lower than the predetermined reference value. | 2014-12-11 |
20140363473 | METHOD FOR PREPARING SPHEROIDS OF HUMAN PRIMARY HEPATOCYTES - The present invention relates to a method for preparing spheroids of human primary hepatocytes. The method comprises culturing of isolated human primary hepatocytes on a polysaccharide scaffold under conditions that allow the formation of hepatocyte spheroids, and subsequently dissolving the polysaccharide scaffold to release the hepatocyte spheroids. The spheroids obtained by the method of the invention are particularly suitable for being transplanted into a subject afflicted with a liver disease. | 2014-12-11 |
20140363474 | ADJUVANTED INFLUENZA VIRUS COMPOSITIONS - The present invention relates to influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to multivalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from at least two influenza virus strains, at least one strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant. | 2014-12-11 |
20140363475 | OIL-IN-WATER EMULSIFIED SKIN COSMETIC COMPOSITION - An oil-in-water emulsion skin cosmetic composition comprising the following components (A), (B), (C), (D) and (E):
| 2014-12-11 |
20140363476 | STABLE VITAMIN C COMPOSITIONS - Disclosed is a composition comprising ascorbic acid or a derivative thereof, a silicone containing compound, and an essential oil, wherein at least 50% of the initial amount of the ascorbic acid in the composition remains stable when the composition is stored for at least 1 month at room temperature. The composition can be non-aqueous. | 2014-12-11 |
20140363477 | Vegan Emulsion - The present invention relates to a vegan emulsion, in particular a food emulsion and/or a cosmetics emulsion. The emulsion according to the invention is a multiple emulsion in which at least 90% of the emulsion droplets of the multiple emulsion have a diameter of 2-10 μm, preferably 4-8 μm. | 2014-12-11 |
20140363478 | COMPOSITION - There is provided an anti-fouling composition comprising (i) a surface coating material; (ii) an enzyme obtained or obtainable from a marine organism; and (iii)(a) a substrate for the enzyme; and/or (b) a precursor enzyme and a precursor substrate, wherein the precursor enzyme and the precursor substrate are selected such that a substrate for the enzyme is generatable by action of the precursor enzyme on the precursor substrate; wherein the enzyme and the substrate are selected such that an anti-foulant compound is generatable by action of the enzyme on the substrate. | 2014-12-11 |
20140363479 | Compositions and methods for treating extracellular parasitic infections - There is disclosed herein a composition for treating extracellular parasitic infections, the composition comprising one or more of the following combinations: at least one quinolone or fluoroquinolone together with at least one tetracycline, iodoquinol, an azole or imidazole; or at least two agents selected from the group consisting of iodoquinol, thiazolidones, tetracycline, nitroimidazoles, cotrimoxazole and diloxanide furoate. There is also disclosed herein a method for treating extracellular parasitic infections in a vertebrate in need of said treatment, wherein said treatment comprises administering to said vertebrate a therapeutically effective amount of (i) a composition comprising a quinolone or fluoroquinolone together with a pharmaceutically acceptable carrier or (ii) a composition of the invention or (iii) a combination of at least one quinolone or fluoroquinolone optionally together with at least one tetracycline, iodoquinol, an azole or imidazole; or (iv) a combination of at least two agents selected from the group consisting of iodoquinol, thiazolidones, tetracycline, nitroimidazoles, cotrimoxazole and diloxanide furoate. | 2014-12-11 |
20140363480 | DEVICE FOR DISCHARGING LIQUID | 2014-12-11 |
20140363481 | BONE REPLACEMENT IMPLANTS WITH MECHANICALLY BIOCOMPATIBLE CELLULAR MATERIAL - A methodology integrating multiscale analysis and design optimization to design a novel bone replacement implant made of a functionally graded cellular material that meets fatigue requirements imposed by cyclic loadings. The pore microarchitecture, described by interconnectivity, porosity, pore size as well as pore topology, is optimally designed for tissue regeneration and mechanical strength. The method can contribute to the development of a new generation of bone replacement implants with a graded cellular microstructure. | 2014-12-11 |
20140363482 | Bioerodible Sustained Release Drug Delivery Systems - The present invention relates to sustained release drug delivery systems, medical devices incorporating said systems, and methods of use and manufacture thereof. The inventive systems feature bioerodible drug delivery devices that include biocompatible solid and biocompatible fluid compositions to achieve desired sustained release drug delivery. | 2014-12-11 |
20140363483 | PHARMACEUTICAL USE OF A COMPOSITION INCLUDING A CARBONACEOUS MATERIAL AND AN ACTIVE PARTICLE - A method of treating or preventing | 2014-12-11 |
20140363484 | FIBROUS BIO-DEGRADABLE POLYMERIC WAFERS SYSTEM FOR THE LOCAL DELIVERY OF THERAPEUTIC AGENTS IN COMBINATIONS - The present invention is related to flexible, fibrous, biocompatible and biodegradable polymeric wafer; consists of more than one polymeric fibers, each one loaded with different therapeutic agents having mutually exclusive synergistic activity. The wafer is capable of delivering the drugs locally in to the diseased site like tumor, inflammation, wound, etc., in a controlled and sustained fashion for enhanced therapeutic effect. The combination of drugs loaded in the wafer is chosen in such a way that the second or consecutive drugs will enhance or improve the therapeutic effect of the first drug. | 2014-12-11 |
20140363485 | WIPE AND METHODS FOR IMPROVING SKIN HEALTH - The present invention relates to methods and products, such as wet wipes and absorbent articles, that are capable of imparting a health benefit when used in the intended fashion. More specifically, the products described herein comprise one or more botanical compounds, which are capable of selectively controlling the balance of flora on the skin. The compounds may enhance the adherence of healthy flora to the surface of skin or mucosa, inhibit the growth of problem flora on or around the skin surface, or inhibit the adherence of problem flora to the surface of skin or mucosa, or any combination thereof. | 2014-12-11 |
20140363486 | METHODS FOR REDUCING OR ALTERING SCAR FORMATION - Glycerophosphate salts have been found to hasten the healing of wounds and minimize the formation of scars, particularly when it is first applied to a wound about 0 to about 7 days after the wound is inflicted. Methods and compositions are provided for treating wounds using a composition comprising an effective amount of glycerophosphate salt. In particular, methods are provided for treating wounds using calcium glycerophosphate (CGP), for accelerating the healing process, reducing pain and scar formation, and for the cosmetic reducing, excision, erasure and/or complete repair of scars (scar revision). | 2014-12-11 |
20140363487 | TRANSDERMAL DELIVERY SYSTEM COMPRISING BUPRENORPHINE - The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenoφhine-impermeable backing layer, and B) a buprenorphine-containing pressure-sensitive adhesive layer on said buprenorphine-impermeable backing layer, the adhesive layer comprising a) at least one polymer-based pressure-sensitive adhesive, b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, and c) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid and linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said analgesically effective amount of buprenorphine is solubilized therein to form a mixture, and the carboxylic acid buprenorphine mixture forms dispersed deposits in the said pressure-sensitive adhesive, wherein said buprenorphine-containing pressure-sensitive adhesive layer is the skin contact layer. | 2014-12-11 |
20140363488 | Adhesive patch - A method of treating Herpes Labialis includes assembling a patch having hydrocolloid particles added to a layer of adhesive to so configure the patch to have a limited absorption of moisture into the patch combined with a permeability of moisture through and out of the patch. The method additionally includes providing the patch to the user and having the user apply the patch to the user's face in treating the Herpes Labialis, and configuring the patch to be less visible when applied to the user's face than a cream is visible when applied to the user's face. | 2014-12-11 |
20140363489 | TREATMENT OF EYE DISEASE - The present invention provides methods and compositions for treating retinal degeneration. One embodiment of the present invention is directed to a method of treating retinal degeneration by administering to a patient in need at least one thiosemicarbazone compound. | 2014-12-11 |
20140363490 | OLIGOMER-CONTAINED NANOPARTICLE COMPLEX RELEASE SYSTEM - An oligomer-contained nanoparticle complex is provided. The oligomer-contained nanoparticle complex of the invention comprises (a) a nanoparticle, (b) a polymer with high molecule weigh, (c) a target molecule, (d) an oligomer, wherein the oligomer is crosslinked with the polymer by the intermolecular hydrogen bonds or electron bonds, and e) a space for active substances, wherein the space for active substances is encapsulated by the nanoparticle. The oligomer-contained nanoparticle complex of the invention has the high stability and fast drug release rate, and would not be largely accumulated in normal tissues. The invention also provides a method for preparing the oligomer-contained nanoparticle complex and the method for releasing drug. | 2014-12-11 |
20140363491 | NOVEL LIPOSOME COMPOSITIONS - The present disclosure provides lipid-containing compositions, including targeted liposomes encapsulating drug, and pharmaceutical formulations thereof, as well as methods for the making and using the lipid-containing compositions, including the use of the targeted liposomes in the treatment of cancer and other diseases. | 2014-12-11 |
20140363492 | INTRACUTANEOUS INJECTION - The delivery of biopharmaceutical and other therapeutic agents parenterally to an animal via a minimally invasive, low pain administration is provided. The agents are delivered to the patient via, e.g., the epidermal, dermal, or subcutaneous layer of the skin in a concentrated fours of injectable paste of slurry. | 2014-12-11 |
20140363493 | LIPID NANOPARTICLES FOR TARGETED siRNA DELIVERY - The present invention addresses a need for improved vehicles for delivering small interfering RNAs (siRNAs). | 2014-12-11 |
20140363494 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TUMORS EXPRESSING EGFR AND GM3 N-GLYCOLYL GANGLIOSIDE (NeuGcGM3) - The present invention relates to pharmaceutical compositions for the treatment of malignant tumors. Particularly those tumors that express EGFR and GM3 N-glycolyl ganglioside targets to enhance the therapeutic effect produced by separated therapies against these targets. The pharmaceutical compositions of the invention include antibodies and/or vaccines against each of the targets. Additionally the present invention relates to methods for applying the compositions of the invention. | 2014-12-11 |
20140363495 | NATIVE AND AGONIST CTL EPITOPES OF THE MUC1 TUMOR ANTIGEN - The invention provides peptides comprising a human cytolytic T lymphocyte (CTL) epitope from the human tumor-associated antigen (TAA) mucin 1 (MUC1) and analogs thereof, which can be used in vaccine prevention or therapy of cancer, as well as a nucleic acid encoding the peptide, a vector comprising the nucleic acid, a cell comprising the peptide, nucleic acid, or vector, and compositions thereof. | 2014-12-11 |
20140363496 | Compositions and Methods for Inducing Nanoparticle-mediated Microvascular Embolization of Tumors - Nanoparticle mediated microvascular embolization (NME) of tumor tissue may occur after systemic administration of PEM, leading to widespread shutdown of vascular flow, hemorrhage, and necrosis. PEM constructs are developed that incorporate large amounts of iron-containing protein, possess high oxygen affinities, and demonstrate delayed nitric oxide binding. Such properties induce selective NME of tumors after extravasation, and will likely enhance the effect of VEGFR TKIs and/or mTOR inhibitors. | 2014-12-11 |
20140363497 | Nanocell Drug Delivery System - Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent. | 2014-12-11 |
20140363498 | HYDROGEL POLYMERIC COMPOSITIONS AND METHODS - Some aspects of this disclosure relate to a method of treating an ophthalmic disease affecting an eye of a patient comprising forming a covalently-crosslinked hydrogel in situ at a peri-ocular, intra-ocular, or intra-vitreal site for controlled release of a therapeutic agent. | 2014-12-11 |
20140363499 | USE OF A PARTICULATE IMMUNOMODULATOR IN CANCER THERAPY - The current invention is directed to a particulate or vesicular formulation of an immune modulating molecule, like e.g. cytokines, as well as uses, methods, compounds thereof. The formulation may be used to treat a range of diseases and conditions, in particular cancer. | 2014-12-11 |
20140363500 | USE OF AN ANTIBODY AND A PARTICULATE IMMUNOMODULATOR - The current invention is directed to particulate or vesicular immunomodulators, like e.g. cytokines, for use in combination therapy with antibodies for treatments of a range of conditions and diseases, in particular cancer, as well as methods, compositions, and kits thereof. | 2014-12-11 |
20140363501 | The protective effects and application of a Lactobacillus rhamnosus on the alleviation of chronic alcoholic liver injury - An anti-oxidative | 2014-12-11 |
20140363502 | Resveratrol-Containing Compositions and Methods of Use for Treatment of Macular Degeneration - The present invention relates to a resveratrol-containing composition capable of modulating gene expression to an extent greater than that observed with resveratrol alone or with calorie restriction. The invention particularly pertains to such resveratrol-containing compositions that comprise resveratrol, a chelator, hyaluronic acid, and/or vitamin D and which upon administration to a recipient, increases the concentration or activity of a survival/longevity gene product and/or decreases the concentration or activity of a gene product that induces or causes cellular damage. Most preferably, the resveratrol-stabilizing composition will comprise the chelator phytic acid (inositol hexaphosphate; IP6), hyaluronic acid, and vitamin D. The invention further pertains to the use of such compositions in the treatment or prevention of cancer, cardiovascular disease, diseases associated with aging, and other conditions and illnesses. | 2014-12-11 |
20140363503 | CHEWABLE SOFT CAPSULES - A matrix formulation for a soft chewable capsule is provided which includes a gel-forming composition, a plasticizer, a polymer modifier, and water. The polymer modifier may be a carboxylic acid or other organic compound that alters the physical and/or chemical properties of the capsule formulation. A chewable soft capsule is also provided, having enhanced organo-leptic and processing properties. An active material may be delivered to a user using this dosage form. A method of forming the chewable soft capsule is also provided. | 2014-12-11 |
20140363504 | ABSORBABLE ENCAPSULATED CALCIUM IN HYPROMELLOSE CAPSULE - An absorbable encapsulated calcium in hypromellose capsule, characterized in that the encapsulated calcium comprises calcium amino acid chelate extracted from soya bean, aspartate, calcium amino acid chelate which is obtained from chelation of aspartate with calcium hydroxide, collagen, lecithin, soya bean extract, lactose, calcium carbonate, in the ratio of 4:8:8:10:8:12:10:40 being capsulated into hypromellose capsule capable of being absorbed in vivo at the small intestine beyond the stomach, which maximize human absorption of calcium. | 2014-12-11 |
20140363505 | NEW COMBINATION - The invention relates to a new fixed dose combination of benazepril with pimobendan. | 2014-12-11 |
20140363506 | FORMULATION FOR PULMONARY ADMINISTRATION OF ANTIFUNGAL AGENTS, AND ASSOCIATED METHODS OF MANUFACTURE AND USE - Formulations are provided for pulmonary administration of an antifungal agent to a patient. Methods of using the formulations in the treatment of antifungal infections are also provided, including treatment of pulmonary aspergillosis with amphotericin B-containing formulations. Methods of manufacturing the formulations to achieve optimum properties are provided as well. | 2014-12-11 |
20140363507 | DENTRIC POLYGLYCEROL SULFATES AND SULFONATES AND THEIR USE FOR INFLAMMATORY DISEASES - The present invention relates to the novel compound classes of dendritic polyglycerol sulfates and sulfonates as well as to their production and use for the treatment of diseases, particularly inflammatory diseases, and to their use as selectin inhibitors and selectin indicators. The dendritic polyglycerol sulfates and sulfonates are also suitable for imaging diagnostics, particularly with respect to inflammatory diseases. | 2014-12-11 |
20140363508 | PHARMACEUTICAL FORMULATIONS OF FLURBIPROFEN AND GLUCOSAMIN - The present invention relates to pharmaceutical formulations of flurbiprofen or a pharmaceutically acceptable salt thereof and glucosamine or salts thereof. Particularly, the present invention relates to a stable formulation of this combination having desired levels of dissolution rate and solubility which comprises at least one polymer having a low glass transition temperature. | 2014-12-11 |
20140363509 | COMPOSITIONS FOR THE TREATMENT OF MUCOUS MEMBRANE DISEASES - Composition comprising at least one active principle, at least one vehicle for said active principle and particles of porous silica, in which the active principle is contained in at least one pore of at least a first portion of such silica particles and in that vehicle, for use in the treatment of a disease of a mucous membrane. | 2014-12-11 |
20140363510 | PHARMACEUTICAL COMPOSITION INCLUDING PIMOBENDAN - A solid formulation includes pimobendan or a pharmaceutically acceptable salt thereof, which is homogenously dispersed with a polyvalent acid and a flavor suitable to animals. | 2014-12-11 |
20140363511 | METHOD OF TREATING MIDDLE EAR INFECTIONS - Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane. | 2014-12-11 |
20140363512 | ORAL PHARMACEUTICAL COMPOSITION - The present invention provides an FTD and TPI-containing oral pharmaceutical composition which can be orally administered and is stable even under high humidity conditions. | 2014-12-11 |
20140363513 | Octreotide Depot Formulation with Constantly High Exposure Levels - The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs). | 2014-12-11 |
20140363514 | CORE-SHELL PARTICLE FORMULATION FOR DELIVERING MULTIPLE THERAPEUTIC AGENTS - A core-shell particle formulation for delivering multiple therapeutic agents is disclosed. More particularly, core-shell particle formulation configured to independently release therapeutic agents from the core and the shell. Moreover, the core-shell particle bearing therapeutic agents enables treatment against the diseases such as cancer, inflammatory and auto-immune diseases. | 2014-12-11 |
20140363515 | BEADLETS COMPRISING HOP ACID SALTS IN A STARCH MATRIX - The present invention relates to a process for production of beadlets comprising hop acids salts in a matrix comprising at least one starch and/or starch derivative, to such beadlets and to the use of such specific beadlets. | 2014-12-11 |
20140363517 | METHODS OF USING KRILL OIL TO TREAT RISK FACTORS FOR CARDIOVASCULAR, METABOLIC, AND INFLAMMATORY DISORDERS - This invention discloses methods of using krill oil and compositions comprising krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. The present invention also relates to methods of using compositions comprising krill oil to modulate biological processes selected from the group consisting of glucose metabolism, lipid biosynthesis, fatty acid metabolism, cholesterol biosynthesis, and the mitochondria respiratory chain. The present invention further includes pharmaceutical and/or nutraceutical formulations made from krill oil, methods of making such formulations, and methods of administering them to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. | 2014-12-11 |
20140363518 | ANTIVIRAL THERAPY WITH A WHOLE, LEECH SALIVA EXTRACT - Methods are provided for isolating and using a whole-saliva leech extract. The methods can include feeding a phagostimulatory agent to a leech; inducing a regurgitation in the leech, the inducing including placing the leech in an environment having a temperature of less than about 0° C.; and, collecting an unrefined, whole saliva in the regurgitation of the cooled leech. The methods can include revitalizing the leech by warming it at a temperature ranging from about 5° C. to about 40° C. Stable, lyophilized, whole-saliva extracts of a leech are also provided, the extract having a stable activity when stored for use at a temperature below about −20° C., the extract maintaining at least 70% of the activity for at least 6 months. The extracts can be used to treat solid tumors, treat liquid tumors, treat diabetes, treat a viral disease, treat a parasitic disease, treat an antibacterial disease, or serve as an anti-oxidant. | 2014-12-11 |
20140363519 | ACTIVATOR OF GENE EXPRESSION OF MOLECULAR CHAPERONE GENE COMPRISING EGGSHELL MEMBRANE COMPONENT AND COMPOSITION THEREOF - To provide an activator of gene expression of molecular chaperone gene and applications thereof. | 2014-12-11 |
20140363520 | WET HAND TOWEL AND METHOD FOR PRODUCING THE SAME - A substrate contains a composition including VOSO | 2014-12-11 |